Vaccines-2013 - OMICS Group

Recommendations

Info

Min-Seok Bae et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAThe stability estimation for Korean national biological reference standards: Bordetella Pertussisand anti-pertussisMin-Seok Bae, Seung-Tae Chung, In Soo Shin, Hyun-Kyung Kang, Jeong-Nam Woo, Ye-Jin Choi, Seul-Ji Jang, Shin-Jung Kang and Chi-Young AhnNational Institute of Food and Drug Safety Evaluation, KoreaBiological products include a wide range of products such as vaccines, blood-derived products, toxins, recombinant therapeuticproteins, cell therapy products, and gene therapy products. Reference standard is a biological material one or more of whoseproperty values (potency, amount, etc.) are sufficiently well established to be used in assessing a measurement method or assigningvalues to other biological materials. According to WHO recommendation, we as national authority, obtain minimum amount ofstandards from WHO international laboratories and establish our own national biological reference standards (NBRSs). A highdegree of stability is one of essential requirements for NBRSs.In this study, stability tested for Bordetella Pertussis Vaccine and anti-pertussis NBRSs were performed. The mouse bodyweight gain test (MWGT), the leukocytosis-promoting test (LPT), and the histamine sensitization test (HIST) are done for thetesting of the specific toxicity of pertussis vaccines. For the anti-pertussis, identification test (Ouchterlony test) was performed.The trend analysis in lymphocytosis promoting units and histamine-sensitizing units were stable but body weight-decreasingunits (BWDU) were decreased. Identification test on anti-pertussis showed clear precipitin lines.Taken together, it has been proposed as follows; Bordetella Pertussis vaccines and anti-pertussis which are made by MFDS asa national biological reference standard showed stable potency.bmsposh@korea.krJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 112
STS. Chitradevi et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USARecombinant heat shock protein 60 (GroEL) of S.Typhi as an effective adjuvant in modulatingthe immunogenicity of Invasion plasmid antigen B (IpaB) of Shigella flexneri against lethalShigella infection in miceSTS. Chitradevi, A. Bansal, G. Kaur, D. Saraswat, M. Singh and S. SaxenaExperimental Biology Division, Defence Institute of Physiology and Allied Sciences (DIPAS), Defence Research and Development Organisation (DRDO), IndiaShigella spp. cause severe bacillary dysentry in humans associated with high morbidity and mortality. The multiple Shigellaserotypes and their resistance to antibiotics warrants the development of vaccine that is protective across all serotypes. Shigellautilizes type III secretion apparatus and translocates the effector proteins into the host cell to initiate the infection. The effectorprotein IpaB (Invasion plasmid antigen B) is necessary for pathogenesis and mediates macrophage cell death. It is the conservedmolecule in all Shigella serotypes. The present study evaluates the adjuvant effect of recombinant GroEL of S. Typhi when coimmunizedwith recombinant IpaB of S. flexneri in mice. IpaB domain region (37 KDa) of S. flexneri was amplified, cloned,expressed in BL-21 E.coli cells and purified. Intra-nasal (i.n.) immunization of mice with IpaB protein alone showed increase inIgG and IgA antibody titers as compared to control mice, but when co-immunized with GroEL, there was two fold increase inantibody titers. Antibody isotyping (IgG1, IgG2a) and cytokines estimation (IFN-γ, IL-4, IL-10) revealed enhanced Th1 and Th2immune responses in co-immunized group. Immunization of mice with recombinant IpaB protected 60-70% of mice from lethali.n. infection of S. flexneri, S. boydii and S. sonnei whereas co-immunization increased the protective efficacy to 80%. This studyshows the potential of GroEL of S. Typhi as an effective adjuvant for the development of broadly protective IpaB based vaccineagainst all Shigella spp.BiographySTS. Chitradevi has completed her M.Sc Microbiology at Annamalai University, Chidambaram, India. She is the Senior research scholar at DefenceInstitute of Physiology and Allied Sciences (DIPAS), Defence Research and Development Organization (DRDO), Delhi, India and pursuing her Ph.Din Life Sciences at Bharathiar University, Coimbatore, India. She was awarded with Tamil Nadu State Council for Science and Technology fellowship,DRDO- Junior research fellowship and DRDO-Senior research fellowship. She recently published her work in the reputed journal Vaccine.chitradevists@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 113
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111: Byung Chul Kim et al., J Vaccines V
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?